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CHAPTER 1
INTRODUCTION
Cholangiocarcinoma is a devastating tumour usually associated with late dia-
gnosis, poor quality of life, and low survival rates. Therapeutic options are limited,
and no definitive treatment other than early surgery has been identified to date.
At this point, therapeutics employing new mechanisms of action are desperately
needed.
Increasing evidence suggests that oncolytic viruses might be a viable treatment
option in many different cancer types. Over the past 50 years, the field of oncolytic
viruses has evolved from very early case reports of single patients to phase III trials
including hundreds of patients, and finally to the first approval of an oncolytic
virus by the United States Food and Drug Administration (FDA) and the European
Medical Agency (EMA) in 2015. These viruses spread preferentially in cancer cells,
exploiting certain aspects of the tumour cell biology and its pathways. Lately, they
have been targeted, shielded, and armed to allow for more efficient tumour reduc-
tion.
Although engineered viruses have been portrayed as dangerous and uncontrol-
lable in popular culture (e.g. ’I Am Legend’ by Warner Bros. Pictures, 2007),
patient safety has been paramount in the development of these new drugs so
far. Both the measles vaccine virus and the vaccinia virus, two oncolytic viruses
used in the majority of the first clinical trials, were developed to protect the pop-
ulation from life-threatening diseases (i.e. measles and smallpox). Hundreds of
millions of vaccinations have been carried out in the last century, eliminating the
2
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smallpox virus and bringing the wild-type measles virus to the verge of extinction.
From what we know today, the adverse effects resulting from this use remain well-
controlled.
In this study, we tested the feasibility of using an engineered, suicide gene-armed
measles vaccine virus in the treatment of cholangiocarcinoma. We evaluated
growth kinetics and tumour death, and then translated these findings into two in
vivo trials.
The main results of this thesis were published in 2013 by our group [1]. Direct cita-
tions from this study are marked accordingly.
In the following chapter, the epidemiology and therapy of cholangiocarcinoma
are summarised briefly (Section 1.1). Then, the biology and epidemiology of
the measles virus are recapitulated (Sections 1.2 and 1.3). Later, the concept of
oncolytic viruses is introduced in detail (Section 1.4), with special emphasis on the
measles vaccine virus (Sections 1.5 to 1.7).
Introduction 4 Cholangiocarcinoma
1.1 Clinical significance of cholangiocarcinoma
Malignant tumours of the biliary tract comprise cholangiocellular and gallbladder
adenocarcinomas as well as a minor (<10%) fraction of papillary tumours [2].
"Cholangiocarcinoma is the second most common form of primary hepatic tumour
(after hepatocellular carcinoma), accounting for approximately 20% of the deaths
from hepatobiliary malignancies, which cause 13% of the total cancer mortality
worldwide [3, 4]. Epidemiologic studies suggest an increasing incidence in West-
ern countries during the last decades [5, 6]." [1] The highest incidences of cholan-
giocarcinoma are found in Thailand, China, and other parts of Southeast Asia, in
part due to a very high incidence of liver fluke [7].
Risk factors with a strong association to cholangiocarcinoma include primary scle-
rosing cholangitis, Opisthorcosis viverrini infection, choledochal cysts, hepatolethi-
asis, and liver cirrhosis [8]. Possible associations have been made to Clonorchis sin-
ensis infection, viral hepatitis B and C infection, and alcohol consumption, as well
[7, 9].
Five-year survival from hepatobiliary malignancies has improved over the last
35 years, yet still remains staggeringly low (3% in the 1980s, 5% in the 1990s, and
15% between 2001 and 2007) [10]. "The only curative option for patients with
gallbladder or bile duct cancer is surgical resection. Unfortunately, most cholan-
giocarcinomas remain clinically silent until having reached an advanced and then
unresectable stage." [1] The rate of resectability has been reported as approximately
70% in distal cancer and 15 to 20% in cases of central bile duct tumours [11]. Al-
though progressingly more aggressive surgical approaches have been developed
in the last years, curative or margin-free resection rates remain less than 70% [12].
Accordingly, the overall five-year survival rate after resection is between 16 to 52%
[13].
Currently, there is no clearly defined standard of care for adjuvant therapy of
cholangiocarcinoma following surgery. Potential benefits of radiotherapy have
been reported; however, these findings are limited to single-centre trials [14, 15]. To
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date, no studies have shown a clear benefit of adjuvant chemotherapy after resec-
tion [11, 16].
In patients with advanced stage cholangiocarcinoma, palliative (chemo-)therapy is
often complicated by cholestasis and recurring cholangitis (a bacterial infection of
the bile ducts) leading to severely reduced quality of life. The ABC-02 trial estab-
lished the combination of cisplatin plus gemcitabine as an appropriate standard of
care for unresectable advanced biliary tract cancer [17]. Following the advent of
targeted therapies in other cancer entities, different phase II/III trials are currently
evaluating the potential benefits of these agents [18].
1.2 Wild-type measles infection and vaccination
Measles is a highly contagious viral disease transmitted by droplet infection caus-
ing fever, malaise, and conjunctivitis, followed by the development of a character-
isting exanthema (Figure 1). 90% of exposed individuals develop the clinical dis-
ease after six to twenty-one days [19]. The case fatality rate is highest in infants and
young children, mostly caused by pneumonia [20].
Severe neurologic complications are rare but usually fatal. These include acute
disseminated encephalomyelitis and subacute sclerosing panencephalitis. The
latter is a degenerative disease of the central nervous system occurring seven to
ten years after measles virus infection (infection at an earlier age increases the
risk). It has been shown that this is caused by persistent infection of the central
nervous system by measles viruses with genetic defects in the M, F, or H proteins
[21].
There is no causal treatment for infection by the wild-type measles virus. Ther-
apy is usually only supportive in nature and includes antipyretics, fluids, and
treatment of bacterial superinfections with antibiotics. For individuals at high
risk for complications (infants, pregnant women without evidence of immunity,
and severely immunocompromised patients regardless of immunologic status),
guidelines recommend therapy with pooled, polyvalent human immunoglobulin
G antibodies within six days of exposure [22].
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Figure 1. Two children exhibiting the characteristic rash caused by infection with the
measles virus. Left panel reproduced from [23], right from [24].
Measles virus was first isolated from the blood of a child with measles (David Ed-
monston) by Enders and Peeble in 1954 [25]. This virus (Edmonston-Enders strain)
was propagated in human and monkey cells. Later, attenuation in chick embryo
fibroblasts produced the Edmonston B strain (the first attenuated live measles
vaccine) [26]. Further passaging in chick embryo fibroblasts produced the Schwarz
strain [27, 28], which served as the standard measles vaccine worldwide and is also
used in this study for virotherapeutic purposes [29].
Vaccination has greatly reduced the worldwide burden of measles virus infection
(as illustrated exemplarily in Figure 2 for the United States), reducing the number
of measles-associated deaths by 80% between 2000 and 2014 [30]. The Robert Koch
Institute (Berlin, Germany) recommends vaccinating children with a quadrivalent
vaccine containing attenuated measles, mumps, rubella, and varicella viruses twice
(at 11-14 months and 15-23 months) [31].
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Figure 2. Yearly measles cases reported in the United States, 1944 - 2011. The first
measles vaccines were licensed in 1963. In 1989, after an increase of measles incidence in
children vaccinated before, a second dose was recommended by the Centers for Disease
Control and Prevention. Adapted from [32, 33]
1.3 Molecular biology of measles virus
The measles virus belongs to the genus Morbillivirus within the Paramyxoviridae
family. These are enveloped negative-strand RNA viruses characterised by two sur-
face proteins F and either H, HN or G. Inside the envelope, the RNA genome and
the N, P, and L proteins needed for viral replication can be found (Figures 3 and 4).
The M protein is situated between the envelope and the nucleocapsid core (as re-
viewed in [34]).
Figure 3. Ultrastructural appearance of a measles virus particle by transmission elec-
tron micrograph. Nucleocapsid protein (NC), Phosphoprotein (P), Matrix protein (M), Fusion
protein (F ), Hemagglutinin (HA) and Large protein (L). Please refer to Table 1 for an extensive
characterisation of these structural proteins and to Figure 4 for a schematic depiction of an
MV particle. Reproduced from [35].
The measles genome is coated by nucleocapsid proteins. It contains six genes
coding for the six structural proteins as well as leader and trailer regions (3’-ld-N-P-
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Figure 4. Morphology of a polyploid measles virus particle containing three genomes.
MV expresses 6 structural proteins: Nucleocapsid protein (N), Phosphoprotein (P), Matrix
protein (M), Fusion protein (F ), Hemagglutinin (H) and Large protein (L). C and V (not
depicted) are non-structural proteins. Adapted from [36].
M-F-H-L-tr-5’). Additionally, the P gene contains open reading frames for the non-
structural C and V proteins. Between these six genes, untranslated regions contain
conserved sequences serving as transcription initiation and termination signals
(as reviewed in [34]). An overview of the viral proteins and their functions can be
found in Table 1.
The measles virus nucleocapsid is released into the cytoplasm of the infected cell
after binding of the H protein to the cellular receptor (SLAM/CD150, Nectin 4,
or CD46) and fusion of both membranes by the activated F protein. This protein
mediates not only fusion between the virus and cell membranes, but can addi-
tionally initiate fusion between infected and uninfected cells (compare Figure 5).
200 µm1000 µm
Microscopy Syncytium
Figure 5. Fluorescence microscopy of Vero cells producing green fluorescent protein
after infection with a modified measles vaccine virus. Syncytia with multiple condensed
nuclei (up to 20) surrounded by cell membranes are visible in the enlarged picture on the
right. Own work.
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Table 1. Characterisation of the structural and non-structural proteins of measles virus. Adapted from
[34, 37]
Protein Function
Structural
proteins
Nucleocapsid
protein (N)
RNA-binding protein, coats full-length viral
(-) sense genomic and (+) sense antigenomic
RNAs to form the helical nucleocapsid tem-
plate
Phosphoprotein (P) binds to N and L proteins during viral tran-
scription and genome replication
Matrix protein (M) interacts with nucleocapsid and plasma mem-
branes, directs intracellular trafficking
Fusion protein (F) mediates virus-cell and cell-cell fusion
Hemagglutinin (H) binds cellular receptors CD461, Nectin 42 and
SLAM/CD1503, hemaglutinates erythrocytes
Large protein (L) RNA-dependent RNA polymerase
Non-
structural
proteins
C inhibits interferon signaling and prevents cell
death
V interferes in interferon signaling
1 expressed on nucleated human cells, wild-type MV cannot bind to CD46 [38, 39]
2 expressed on lymphoid cells [40, 41]
3 expressed on epithelial cells [42, 43]
After release of the nucleocapsid, primary transcription by the viral RNA-dependent
RNA polymerase, a complex formed by P and L proteins, produces mRNA encond-
ing for the viral proteins. The transcription, starting at the 3’ end of the genome,
is repeatedly terminated and reinitiated in the non-coding regions between the
different genes [44, 45]. If the polymerase fails to recognise the gene start signal, it
detaches from the template and does not reinitiate the transcription. This leads to
a transcription gradient as illustrated in Figure 6. Importantly, this gradient affects
transgenes introduced into the genome likewise.
After accumulation of sufficient amounts of free N protein in the cell, the RNA-
dependent RNA polymerase starts replication of the antigenome (a full-length
copy of the genome in 5’-3’ orientation) [46, 47]. This antigenomic RNA is then
used as a template for the replication of the genome in 3’-5’ orientation. The
assembled nucleocapsid is attached to the M protein, which is located at the cyto-
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plasmatic side of the cellular plasma membrane. The M proteins, in return, interact
with the F and H transmembrane glycoproteins [48]. The viral particles are released
by budding from the host cell [34].
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Figure 6. Transcription gradient of mRNA after MV infection (schematic). Adapted from
[44]
Wild-type measles virus (MV) as well as measles vaccine virus (MeV) cannot infect
rodent animals due to lack of a cellular receptor. Therefore, the oncolytic effect of
measles virus can only be determined in human xenograft models in immunodefi-
cient mice (as performed in this study) or transgenic mice that express the human
CD46 receptor [49, 50].
1.4 Oncolytic virotherapy
Virotherapy is the use of viruses in the treatment of medical conditions. One aspect
of this is using viruses as vectors for the delivery of gene therapy. The latest break-
through in this field has been the approval of alipogene tiparvovec (developed by
Uniqure) for the treatment of lipoprotein lipase deficiency by the European Medi-
cines Agency in 2012 [51]. Here, an intact copy of the lipoprotein lipase is delivered
to muscle cells by a non-replicating adeno-associated virus serotype 1 vector
[52].
The second aspect of virotherapy is the treatment of cancer by replicating oncolytic
viruses that preferentially infect and kill cancer cells. Beyond the destruction of
these cells by lysis, oncolytic viruses often lead to stimulation of a host antitumour
immune response which is instrumental for the systemic antitumoural effect of on-
colytic viruses [53].
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Publications reporting the use of oncolytic viruses as cancer therapeutics date back
to as early as 1948 [54–56], although tumour regression after rabies vaccination
was reported as early as 1912 [57, 58]. The first clinical trials using oncolytic viruses
were published in the following years, employing viral hepatitis [59], rabies [60],
West Nile virus/Egypt 101 virus [61, 62], or Adenoidal-Pharyngeal-Conjunctival
viruses [63].
"In the last years, a variety of viruses from different families have been tested pre-
clinically and clinically, including adenovirus, herpes simplex virus, vaccinia virus,
reovirus, vesicular stomatitis virus, Newcastle disease virus, and measles vaccine
virus [53, 57, 58, 64]." [1]
After the death of Jesse Gelsinger in 1999 following an adenovirus-based gene ther-
apy trial [65, 66], patient safety in clinical trials involving viral vectors came into
the spotlight. Therefore, vectors that had previously been used as vaccines, often
administered hundreds of millions of times with an evidentiary safety record (e.g.
measles vaccine virus [29] and vaccinia virus [67, 68]) became the frontrunners in
the first clinical trials of virotherapy.
A multitude of phase I, II, and III virotherapy trials have been initiated [69, 70]:
Oncolytic viruses in stage IIb/III trials include Reolysin (a reovirus developed by
Oncolytics Biotech) in combination with paclitaxel and carboplatin for patients
with platinum-refractory head and neck cancers [71], JX-594 (a vaccinia virus en-
coding granulocyte macrophage colony-stimulating factor (GM-CSF) developed by
Jennerex) for patients with sorafenib-resistant advanced hepatocellular carcinoma
[72], and CG0070 (an adenovirus expressing GM-CSF, developed by Cold Genesys)
for patients with non-muscle invasive bladder cancer who have failed bacillus
Calmette-Guérin therapy [73].
In 2005, H101, an replication-selective adenovirus developed by Sunway Biotech,
was approved for the treatment of head and neck cancer in China and thus became
the first approved oncolytic virus worldwide [74, 75]. Later, in 2015, talimogene
laherparepvec (developed by Amgen) became the first oncolytic virus to be ap-
proved in the United States and the European Union for the treatment of unresect-
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able stage III/IV melanoma. This vector is an attenuated oncolytic herpes simplex 1
virus expressing GM-CSF [76, 77].
1.5 Measles vaccine virus as a potent vector for virotherapy
An early case report, dating back as far as 1949 [78], as well as a series of case re-
ports published in the 1970s, suggested that infection with wild-type measles virus
has anti-tumour effects in haematologic malignancies [79–83]. Figure 7 summar-
ises one of these reports. However, only in the mid-1990s, when the first systems al-
lowing rescue of measles vaccine virus from cloned DNA were developed [84, 85],
research of MeV-based anti-cancer therapy started.
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lymph-node metastasis.27 In another study, 33 
patients with advanced solid tumors inhaled 
MTH-68/H (an in vitro passaged NDV strain) 
twice weekly;28 objective responses were reported 
in 7 of these patients including those with lung 
and colon cancers. Similarly, when daily intrave-
nous MTH-68/H was given to 15 patients with 
glioblastoma,29,30 tumor shrinkage occurred in 7 
patients, although interpretation of these results 
is complicated by concomitant treatments.
Vaccinia virus
Intratumoral treatment with vaccinia vaccine 
strains has resulted in significant and repro-
ducible efficacy in numerous clinical trials. 
In contrast to reports with adenoviruses and 
mumps, vaccinia-induced responses were in 
some cases durable, complete and distant from 
the site of injection. Results were published from 
several clinical trials (n = 48) and case reports or 
series (n = 7)15–20 (Table 3). No serious adverse 
events were reported. The first three trials (n = 44) 
evaluated the use of non-engineered vaccinia 
virus administered by intratumoral injection 
to patients with metastatic melanoma.16,19,21 
Mild flu-like symptoms were reported and 
objective responses, including complete regres-
sions, occurred at the injection site in 25 patients 
(57%). Tumor responses were durable in many 
cases and regression in tumors that were not 
injected was demonstrated. Repeated dosing 
was feasible and led to subsequent responses. 
A total of six patients were reportedly free of 
disease after follow up of ≥2 years. Similarly, in 
a report of four patients with advanced mela-
noma treated once with vaccinia, three patients 
were rendered free of disease at 1.5, 2, and 6 years 
post-treatment, respectively.15 Viral spread to a 
non-injected, regressing metastasis was noted 
in one patient. Finally, delivery of vaccine virus 
by instillation into the bladders of patients with 
superficial cancers was shown to be safe and led 
to intratumoral virus replication.18
Intravenous efficacy has been demonstrated 
with vaccinia viruses. Intravenous vaccinia treat-
ment- induced responses were described in three 
patients. Objective tumor responses occurred in 
the lungs of two patients with metastatic renal 
and lung adenocarcinoma.17 A third patient 
with multiple myeloma had an objective sero-
logic (M-spike) response20 (Figure 3C). In addi-
tion, intradermal vaccination with vaccinia led 
to dissemination of the virus and subsequently 
led to complete remission of CLL.8 
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Figure 3 Tumor responses following incidental viral infection, vaccination 
or treatment with non-engineered virus strains. (A) Complete regression of 
Burkitt’s lymphoma (white arrow) over 2 weeks in a patient experiencing 
acute measles infection. Permission obtained from Elsevier © Bluming 
AZ and Ziegler JL (1971) Lancet 2: 105–106.4 (B) Complete hematologic 
response of chronic lymphocytic leukemia following patient vaccination 
with vaccinia and subsequent virus dissemination. Permission obtained 
from American Medical Association © Hansen RM and Libnoch JA (1978) 
Arch Intern Med 138: 1137–1138.8 (C) Major M-spike response in patient 
with multiple myeloma during chronic intravenous therapy with attenuated 
vaccinia strain AS. Reproduced from Kawa A and Arakawa S (1987) Jpn J Exp 
Med 57: 79–81.20 Abbreviations: IgA, immunoglobulin A; NK, natural killer 
cells; PE, plasma exchange.
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Figure 7. Regression of Burkitt’s lymphoma after infection with wild-type measles.
Two weeks after the diagnosis of Burkitt’s lymphoma (left picture), an eight-year-old African
boy developed a characteristic measles exa thema. Over the course of the next two weeks,
the tumour regressed without additional therapy (right picture). The boy remained tumour-free
for the next fo r months, when the case report was published. From [80].
Measles vaccine virus has been shown to be an oncolytic vector infecting a broad
range of tumour entities and is currently under clinical investigation as a new treat-
ment modality against ovarian cancer [86], multiple myeloma, and glioblastoma
multiforme (reviewed in [87, 88]).
Regarding the safety profile of measles vaccine virus, no dose-limiting toxicity
has been reached so far, suggesting a very safe vector system [89]. The safety
of administering measles vaccine virus via different routes have been evalu-
ated in recent studies: Intrahepatic injections of suicide gene-encoding oncolytiv
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MeV (MeV ld-SCD) in conjunction with a systemic 5-FC prodrug administra-
tion was found to be safe in both transgenic mice and rhesus macaques [90].
"Moreover, clinical studies have shown that intravenous, intraperitoneal and
intracerebral injections of MeV-based virotherapeutics are well-tolerated [86]."
[1]
The preferential spread in tumour cells has been attributed, at least in part, to
an overexpression of regulatory membrane-bound proteins including CD46 [91].
CD46 is typically not expressed sufficiently on nontransformed cell to allow for
direct infection by measles vaccine virus [92]. Additionally, some tumours are
deficient in their innate antiviral response, which renders them more susceptible to
viral infection than non-transformed cells [93, 94].
1.6 Arming of oncolytic viruses
"To enhance the antitumour effect of oncolytic viruses, these vectors have been
armed with suicide genes that convert nontoxic prodrugs into toxic substances,
leading to a localised/restricted chemotherapy at sites of viral gene expression and
thus to minimised systemic side effects compared with conventional chemother-
apies (overview in [95])." [1]
"For oncolytic measles vaccine virus, arming with Escherichia coli purine nucleoside
phosphorylase, which toxifies fludarabine or 6-methylpurine-2’-deoxyriboside, has
shown preclinical efficacy in lymphoma [96, 97], pancreatic cancer [98], and an im-
munocompetent model of murine colon carcinoma [99]. However, fludarabine can
cause cytotoxicity when administered systemically [100]." [1]
In this study, a measles vaccine virus vector expressing SuperCD, a fusion of
yeast cytosine deaminase and yeast uracil phophoribosyltransferase, is used (first de-
scribed by Erbs et al. [101]). These enzymes convert the clinically approved
antimycotic 5-fluorocytosine (5-FC) into the chemotherapeutic 5-fluorouracil (5-
FU) and further into 5-fluorouracil monophosphate. This leads to inhibition
of DNA and protein synthesis [102], which is detailed extensively in Figure 8.
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Figure 8. Mechanisms of toxification of 5-fluorouracil. The major metabolites important
in the process of 5-FU toxification are (i) 5-fluorouridine triphosphate, which is incorporated
into RNA; (ii) 5-fluorodeoxyuridine triphosphate, which is incorporated into DNA; and (iii) 5-
fluorodeoxyuridine monophosphate, which inhibits deoxythymidine monophosphate synthesis.
5-FU is converted to 5-fluorouridine monophosphate either directly by orotate phosphoribosyl-
transferase or indirectly by uridine phosphorylase and uridine kinase. Subsequently, 5-FUMP
is phosphorylated to its diphosphate and either hydrolysed to 5-fluorodeoxyuridine diphos-
phate by ribonucleotide reductase or further phosphorylated to 5-fluorouridine triphosphate.
Phosphorylation or dephosphorylation of 5-FdUDP leads to either 5-FdUMP or 5-FdUTP.
SuperCD is a fusion protein of yeast cytosine deaminase and yeast uracil phosphoribosyl-
transferase. CD enables the deamination of 5-FC, which enters the cell through diffusion, to
5-FU, thereby allowing toxification in mammalian cells. UPRT catalyses the conversion of
5-FU to 5-FUMP. Adapted from [102].
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A potent effect of cytosine deaminase in suicide gene therapy was first shown in 1992
[103]. Later, this enzyme was used in combination with uracil phophoribosyltrans-
ferase [104], which is thought to bypass the rate-limiting step of 5-FU metabolism:
dihydropyrimidine dehydrogenase, which rapidly converts 5-FU to dihydrofluor-
ouracil (an inactive metabolite) and is expressed in all tissues [105].
The fusion protein SuperCD was later reconstructed in the laboratory of Professor
Ulrich Lauer in 2005 [101, 106]. Recently, an armed measles vaccine virus express-
ing these enzymes was used for chemovirotherapy of head and neck squamous cell
carcinoma [107].
5-fluorouracil is used as a component of standard chemotherapy in a variety
of tumours, most notably including esophagogastric, colorectal and pancreatic
carcinoma (compare the German S3-guidelines [108–110]). Because of its rapid in-
trahepatic degradation by dihydropyrimidine dehydrogenase, 5-fluorouracil is mainly
administrated intravenously [105]. Methods to allow oral administration primar-
ily include capecitabine, which is an oral prodrug converted to 5-fluorouracil
in the liver and in the tumour. Capecitabine has been shown to be equival-
ent to 5-FU-based chemotherapy for both gastric [111] and colorectal cancer
[112].
1.7 Generation and rescue of recombinant MeV
To produce genetically modified measles virues, different components are needed:
Modified measles virus cDNA (for example, encoding a suicide gene or a reporter
protein) can be constructed by restriction cloning. In addition to this engineered
genome, the N, P, and L proteins are needed in the producer cells to allow for as-
sembly and replication (termed rescue).
In one of these systems, baby hamster kidney cells are stably transfected with a
plasmid expressing phage T7 RNA polymerase under the control of a cytomega-
lovirus promoter [113]. For rescue of the virus, these cells are transfected with a
plasmid containing the genomic cDNA and plasmids encoding the viral proteins
N, P, and L under the control of the T7-Promotor. This system is a refinement of
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the first T7 polymerase-based system first described by Radecke et al. in 1995
[84].
Another system allows rescue of MeV in different cell lines. "For this, the viral
cDNA is inserted into a plasmid containing regulatory sequences (promoter and
terminator) derived from cytomegalovirus which are recognised by the cellular
RNA polymerase II." [1] Vero cells are then transfected with the viral plasmid,
and plasmids encoding for N, P, and L. This system was developed by Professor
Wolfgang Neubert and his laboratory and is described by Lampe et al. in [114] and
[115].
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1.8 Aim of this thesis
"To date, there have been only a very limited number of publications testing
virotherapy against cholangiocarcinoma. These investigations employed either
adenovirus [116–119], herpes simplex virus [120], or vaccinia virus [121] enhanced
by cytosine deaminase/5-fluorocytosine [116, 117], uracil phosphoribosyltransferase/5-
fluorouracil [118], and/or radiotherapy [116–118]. No studies have involved the
measles vaccine virus so far." [1]
Thus, we sought to evaluate a new measles vaccine virus based suicide gene ther-
apy for the treatment of cholangiocarcinoma. Different vectors with 100% genetic
identity to the Schwarz vaccine strain [27] armed with a prodrug convertase with
enhanced efficacy, SuperCD [106], had previously been constructed by our collab-
orators.
First, we tested whether these vectors are able to infect and replicate in cholan-
giocarcinoma cell lines. Then, we quantified the efficacy of tumour cell killing by
the viruses alone as well as in combination with the prodrug. Later, we translated
these findings into two xenograft mouse trials in which tumour growth in an in vivo
model could be evaluated.
CHAPTER 2
METHODS
2.1 Methodical remarks
All materials were stored and used according to the manufacturer’s specifications.
Sterilisation of materials was performed at 120 ◦C and a pressure of 2 bar for 20
minutes in a Systec Autoklav 3850 EL. Consumables and reagents are listed in
Chapter 6. Unless specified otherwise, all chemicals were obtained from Merck,
Carl Roth, Sigma-Aldrich, and Becton-Dickinson.
2.2 General techniques of cell culture
All cell lines were grown in a humidified atmosphere at 37 ◦C, containing 5% CO2.
RBE, TFK-1 and HuCCT1 were cultured in Roswell Park Memorial Institute 1640
cell culture medium (RPMI-1640 [122]), supplemented with 10% heat-inactivated
fetal bovine serum (FBS) and L-Glutamine. The Vero kidney cell line was cul-
tured in FBS- and L-Glutamine-supplemented Dulbecco’s Modified Eagle Medium
(DMEM [123]). The addition of antibiotics or fungicides was not necessary. Cell
lines were regularly tested for mycobacterial infection, via a polymerase chain reac-
tion detection kit.
For routine passaging, cells were washed with Phosphate-Buffered Saline (PBS)
once, treated with 0.05% Trypsin-EDTA at 37 ◦C for 10 to 15 minutes, and quenched
with cell culture medium. Cell clumps were disrupted by repeated pipetting.
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In order to seed appropriate cell numbers in the experiments, cells were counted
with the help of an improved Neubauer haemocytometer as described by Strober et
al. [124].
For cryopreservation of cells [125], an appropriate number of cells (approximately
1× 106 cells/ml) was suspended in freezing buffer (70% RPMI-1640 or DMEM,
20% FBS and 10% dimethyl sulfoxide) and frozen at 1 ◦C/min in cryogenic vials.
Vials were stored in an ultra-low temperature freezer (−145 ◦C), or in liquid phase
nitrogen, for long-term storage. When needed, vials were thawed at 37 ◦C and pre-
warmed cell culture medium was added (five times the freezing buffer volume).
The suspension was centrifuged at 150 xg for 5 minutes to remove supernatant,
then resuspended in the appropriate cell culture medium and transferred to a cell
culture flask.
Cells were visualized by phase contrast microscopy (Olympus CK40). For fluores-
cence microscopy, an Olympus IX50 (attached to a F-View camera system) was
used with the corresponding filters (excitation/emission): eGFP: 489 nm/509 nm;
DsRed: 556 nm/589 nm; Alexa Flour 546: 556 nm/573 nm. Pictures were acquired
and handled with SIS Analysis 3.1 software.
2.3 Cell lines
Three different human cholangiocarcinoma cell lines were used in this study: RBE
cells [126] were isolated from a 64-year-old Japanese woman with an intrahepatic
cholangiocarcinoma. Another intrahepatic cholangiocarcinoma cell line (HuCCT1,
[127]) was established from cells recovered from malignant ascites of a 53-year-old
Japanese male. The TFK-1 cell line [128] was established from an extrahepatic
cholangiocarcinoma, which had occurred in a 63-year-old Japanese man. Accord-
ing to the original publications, cell number doubling times are 45, 55 and 37 hours,
respectively [126–128].
Under culture conditions, RBE and HuCCT1 cells form an adherend monolayer,
when grown on tissue culture-treated polystyrene. TFK-1 cells tend to grow on top
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of neighbouring cells, even after very few cell cycles and are, consequentially, easily
detached during medium changes or in assays (Figure 9).
Microscopy	0h	Control	
TFK-1	 HuCCT1	RBE	
200	µm	
Figure 9. Representative phase contrast images of human cholangiocarcinoma cell
lines 24 hours after seeding. RBE and HuCCT1 cell lines derive from intrahepatic cholan-
giocarcinomas, TFK-1 was established from an extrahepatic cholangiocarcinoma. The scale
bar (200 µm) in the left panel applies to all panels.
Vero cells [129] were used for the production of measles vaccine virus in this study.
Originally, these cells were isolated from kidney epithelial cells of an african green
monkey. Vero cells are interferon-deficient [130] and can be used for the propaga-
tion of a variety of different viruses, including cell-based vaccine virus production
[131].
RBE and HuCCT1 cells were purchased from Riken Cell Bank (RIKEN BioResource
Center, Tsukuba, Japan). The TFK-1 cell line was a kind gift from Dr. Hans-Dieter
Nischalke (Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany). Vero cells
were purchased from the German Collection of Microorganisms and Cell Cultures
(Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Ger-
many).
2.4 Flow cytometry
In order to quantify CD46 expression, cells were plated and allowed to attach.
After washing with PBS, cells were detached with Accutase and transferred into
a flow cytometry tube. After washing (add 4 ml PBS, centrifuge at 1000 xg and
4 ◦C for 5 min), 5× 105 cells were diluted in 50 µl FACS-Buffer (10% FBS in PBS)
and blocked with 10 µl of pooled, polyvalent human IgG antibodies (at 4 ◦C for 5
min).
Cells were labelled with either a monoclonal mouse IgG1 anti-CD46 antibody or a
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monoclonal mouse IgG1 isotype control, conjugated to phycoerythrin (both diluted
1:20 in FACS-Buffer and incubated at 4 ◦C for 30 min). After another washing step,
cells were resuspended in 200 µl FACS-Buffer and fixed with 100 µl 4% paraformal-
dehyde (in PBS). Flow cytometry analysis was performed on a FACS Calibur flow
cytometer, using Cell Quest, and analyzed with WinMDI. The mean fluorescence
index (compare [92]) is the ratio of the mean FL-2 height of antiCD46-stained cells
and the respective isotype control.
Additionally, the rate of MeV infection was determined by flow cytometry. Here,
cholangiocarcinoma cells were plated in 6 well plates (2× 105 cells/well) and
infected at an MOI of 0.01, 0.1 or 1. The amount of virus used is expressed as mul-
tiplicity of infection (MOI), meaning number of plaque forming units (pfu) per cell
(as determined by endpoint dilution assay, compare Section 2.6). After three hours
and every 24 hours thereafter, cells were washed with PBS, detached with Accutase,
and transferred into a flow cytometry tube. After washing (see above), cells were
resuspended in 200 µl FACS-Buffer and fixed with 100 µl 4% paraformaldehyde
(in PBS). The ratio of DsRed-positive cells was determined by flow cytometry ana-
lysis on a FACS Calibur flow cytometer, using Cell Quest and analyzed with Win-
MDI.
2.5 Modified measles viruses
Overall, three different viruses were used in this study (compare Figure 10). All
were provided either by laboratory colleagues (Dr. rer. nat. Johanna Lampe) or by
collaborators (Group of Professor Wolfgang Neubert). The author wishes to ex-
press his deep gratitude for this support.
Professor Wolfgang Neubert and his laboratory (Max Planck Institute of Biochem-
istry, Martinsried, Germany) kindly provided MeV P-SCD and MeV P-DsRed (res-
cued in a T7 polymerase-based system), as well as the cDNA used in the construc-
tion of MeV ld-SCD. The latter was then rescued in a CMV promotor/RNA poly-
merase II system by Dr. rer. nat. Johanna Lampe, as part of her doctoral thesis in the
laboratory of Professor Ulrich Lauer. The backbone for these viruses is the Schwarz
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vaccine strain.
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MeV P‐SCD and MeV P‐DsRed
N P * F H LM
MeV ld‐SCD
MeV Gene Maps V1
Figure 10. Schematic representation of the MeV P-SCD, MeV P-DsRed, and MeV ld-
SCD genomes. "Open reading frames (purple arrows) encoding for SuperCD (yeast cytosine
deaminase fused to uracil phosphoribosyltransferase), or DsRed, were inserted into an empty
additional transcription unit (*) at genome position 3 of the Schwarz measles vaccine strain"
[1], in order to generate MeV P-SCD and MeV P-DsRed, or at genome position 1, for MeV
ld-SCD, respectively. The open reading frames encoding the measles vaccine virus proteins
are depicted as white arrows: Nucleocapsid protein (N), Phosphoprotein (P), Matrix protein
(M), Fusion protein (F), Hemagglutinin (H) and Large protein (L). Reproduced from [1].
2.6 Production and titration of MeV
Measles vaccine viruses (MeV P-DsRed, MeV P-SCD, MeV ld-SCD) were propag-
ated in Vero cells. For this, 1× 107 cells were seeded in 15 cm plates. The next day,
cells were washed with DBPS once and inoculated at MOI 0.03 in Opti-MEM. For
the infection, the virus was thawed on ice, vortexed and diluted in OPTI-MEM.
Cells were exposed to 10 ml Opti-MEM containing viral particles at 37 ◦C for three
hours, and gently moved every 20 minutes to ensure sufficient distribution of the
virus.
After three hours, medium was replaced with 20 ml DMEM supplemented with
10% FBS. 54 hours later, when most cells were infected, the supernatant was
discarded and cells were scraped into 1 ml Opti-MEM per plate. The cell solu-
tion was frozen in liquid nitrogen and rethawed in water at 37 ◦C once (we
found no appreciable benefit (i.e. higher viral titers), using a higher number
of freeze/thaw cycles compared to one cycle). After centrifugation (1.900 xg,
4 ◦C, 15 min), the supernatant was aliquoted into cryogenic vials, and stored at
−86 ◦C.
Viral titers were determined for each produced batch, by endpoint dilution assay,
expressed as TCID50 (50% tissue culture infective dose, amount of virus needed
to cause pathological change in 50% of the cell cultures inoculated). These assays
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were performed in duplicates and repeated three times. 5× 104 cells/well were
plated in a 96 well plate. The following day, a 96 well plate with 270 µl/well of
DMEM supplemented with 5% FBS in the first twelve wells was prepared: 30 µl of
the viral stock was added to the first well and the content was mixed thoroughly.
Then, by transferring and mixing 30 µl of the virus solution to the adjacent well
repeatedly, 12 dilution factors (spanning from 10−1 to 10−12 ) were generated and
30 µl of the diluted solutions were transferred to each well containing Vero cells in
octuplicate.
After 96 hours, plates were inspected microscopically for cythopathic effect of
the virus (syncytia formation) and for presence of red fluorescence (only for MeV P-
DsRed).
For viruses not expressing a reporter gene (MeV P-SCD, MeV ld-SCD), readout
was simplified by indirect immunofluorescence staining. After 96 hours of incuba-
tion, wells were washed with PBS, fixed with 4% formaldehyde (CH2O, in PBS)
for 10 minutes at room temperature, and again washed with PBS. Next, to prevent
non-immunological binding of the primary antibody to other sites and permeabil-
ize cell membranes, wells were incubated with Tris-buffered saline containing FBS
and Triton (50 mM Tris(hydroxymethyl)aminomethane (NH2C(CH2OH)3) (adjus-
ted to pH 7.5 with HCl), 150 mM NaCl, 0.02% Triton X-100 and 1% FBS). Cells
were stained with a polyclonal mouse IgG antibody directed against the MeV nuc-
leoprotein (diluted 1:1000 in TBS with 0.02% Tween) for 30 minutes, washed with
TBS-Tween (three times) and incubated with the secondary antibody (polyclonal
goat IgG antibody directed against both the heavy and light chain of mouse IgG
conjugated to Alexa Fluor 546, diluted 1:1000 in TBS-Tween) for 30 minutes. After
washing with TBS-Tween (three times), PBS was added to allow phase contrast and
fluorescence microscopy.
After evaluating each well for virus-associated cytopathic effects and flourescence,
viral titers were calculated by the method of Spearman [132] and Kärber [133]:
TCID50/ml = 10(f - d/2 + (d x S) + g), where f is the log of the first dilution, d is the log
of the dilution factor, S is the sum of the fraction of positive cells per dilution factor
and g is the log of the volume used.
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In this study, the TCID50 was converted into plaque forming units by multiplying
the TCID50 with 0.69. This number derives from applying the Poisson distribution
[134]: P(o) = e-m, where P(o) is the proportion of negative wells (i.e. TCID50=ˆ 0.5)
andm is the mean number of infectious units per volume.
However, recent studies found that the TCID50 is proportional to e-y ≈ 0.56, where
y is the Euler-Mascheroni constant (theoretical calculations in [135], validated in
[136] by Monte Carlo simulations).
Because these two studies were published after completion of the experiments, the
factor of 0.69 as determined by the Poisson distribution is used throughout this
study.
2.7 Growth curves
2× 105 cells/well human cholangiocarcinoma cells were plated in 6 well plates
and allowed to attach. After washing with PBS, cells were infected with MeV P-
DsRed in 1 ml Opti-MEM, at an MOI of 0.1 for three hours (see Section 2.6).
After infection, cells were washed with PBS (three times) and RPMI-1640, con-
taining 5% FBS, was added into the wells. Directly after the first medium change
(time point: three hours) and every 24 hours after infection, the supernatant of one
well (1 ml) was collected and these cells were scraped into 1 ml Opti-MEM. Both
samples were stored at −86 ◦C. After collecting samples for all time points, the vi-
als were thawed (2 min at 37 ◦C), vortexed (10 to 15 seconds) and centrifuged (3000
rpm for 2 min).
Then, viral titers were determined by endpoint dilution assay (compare Section 2.6).
In contrast to evaluating the titers after virus production, the protocol was altered
to account for the expected smaller amount of virus in the samples: The first step
of dilution was omitted, only eight serial 1:10 dilutions were prepared and 50 µl of
each dilution were added to the Vero cells.
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2.8 SDS-PAGE and western blotting
Cells were seeded in 10 cm plates (2× 106 cells/plate) and later infected at an
MOI of 0.1, with either MeV P-SCD, MeV P-DsRed, or mock-infected, as de-
scribed in Section 2.6. Fifty-four hours after infection, cells were washed with PBS
and scraped into lysis buffer (80 mM Tris (adjusted to pH 7.6 with HCl), 150 mM
NaCl and 1% Nonidet-P40). The cells were lysed by three freeze/thaw-cycles
(liquid nitrogen and water bath or heating block at 37 ◦C) and the remaining cell
debris was spun down (7000 xg, 4 ◦C, 10 min). The supernatants were stored at
−86 ◦C.
The protein concentrations of the samples were determined by the Bradford pro-
tein assay [137]. This assay is based on a shift of the absorption maximum of
Coomassie Brilliant Blue G-250 from 465 nm to 595 nm after binding to mostly
arginyl and lysyl residues of proteins. Therefore, an increase in protein con-
centration leads to an increased measurable absorption. For this assay, the
samples were diluted 1:20 in H2O and 10 µl of this dilution were pippeted into
a clear bottom 96 well plate. The optical density was measured at 595 nm in
a microplate reader after the addition of 200 µl of dye reagent (diluted 1:5 in
H2O). Bovine serum albumin was diluted to at least four different concentra-
tions, covering the expected range of protein concentrations in the samples
and measured likewise. By linear regression, a standard curve was fitted us-
ing these standards and the protein concentrations of the samples were calcu-
lated.
Polyacrylamide gel electrophoresis (SDS-PAGE) was used for molecules according
to their linearized size through a gel matrix. Adding sodium dodecyl sulfate (an
anionic tenside) linearises proteins (by denaturing secondary structures and non-
disulfide-bonds) and charges them negatively roughly proportional to size [138].
The stacking and resolving gels were prepared consecutively in a Biorad Mini Pro-
tean 3 electrophoresis system: First, the resolving gel (Table 2) was filled into the gel
cassette, overlaid with isopropanol and allowed to solidify. After approximately 30
minutes, the isopropanol was removed, the surface was washed with H2O and the
Methods 26 SDS-PAGE and Western Blotting
stacking gel (Table 2) was filled into the cassette. A 10-slot comb was inserted im-
mediately afterwards.
Table 2. Recipes for resolving and stacking gels used in SDS-PAGE.
10% Resolving Gel (15 ml) 3% Stacking Gel (8 ml)
30% acrylamide mix 5 ml 1.3 ml
1 M Tris1 – 1 ml
1.5 M Tris2 3.8 ml –
10% SDS3 0.15 ml 0.08 ml
10% APS4 0.15 ml 0.08 ml
TEMED5 0.006 ml 0.008 ml
H2O 5.9 ml 5.5 ml
1 adjusted to pH 6.8 with HCl
2 adjusted to pH 8.8 with HCl
3 Sodium dodecyl sulfate (CH3(CH2)11SO4Na)
4 Ammonium persulfate ((NH4)2S2O8)
5 Tetramethylethylenediamine ((CH3)2NCH2CH2N(CH3)2)
After solidifying, 20 µg of protein and 5 µl of Roti-Load (a modified Laemmli load-
ing buffer) were diluted up to a total of 20 µl with PAGE running buffer (25 mM
Tris (adjusted to pH 8.3 with HCl), 190 mM glycine and 0.1% SDS). The samples
were denatured at 95 ◦C and loaded onto the gel, together with a molecular weight
marker (Full-Range Rainbow Marker, Mr 12000 to 225000). The run was started at
90 V for 20 minutes, then the voltage was increased to 140 V for approximately 3
hours.
Following SDS-PAGE, proteins were transferred onto polyvinylidene difluoride
membranes (Hybond-P) by electroblotting. Membranes were activated in meth-
anol (15 seconds), then washed in H2O, and transfer buffer (43 mM Tris, 39 mM gly-
cine and 20% Methanol). Gel and membrane were enclosed with two Whatman pa-
pers and one sponge on each side, soaked in transfer buffer and blotted at 400 mA
for 2 hours.
After blotting, the membrane was cut between the expected molecular weights
of the proteins (visualized by the marker): 116 kDa (human vinculin), 58 kDa
(measles vaccine virus nucleoprotein) and 42 kDa (SuperCD). The membrane
was blocked with Roti-Block for human vinculin and SuperCD and with 5%
cow milk in TBS-Tween for MeV nucleoprotein (at 4 ◦C for 12 hours). Next, the
membranes were washed in TBS-Tween twice and incubated with the primary
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antibodies at 4 ◦C for four hours. Surplus antibodies were washed off with TSB-
Tween three times. Incubation with the secondary antibodies was performed at
room temperature for one hour and surplus antibodies were removed likewise.
The primary and secondary antibodies used for western blotting are listed in
Table 3. Washing, blocking and incubating were performed on an orbital shaker.
Table 3. Primary and secondary antibodies used for western blotting.
targeted against type & clonality species diluted in
Human Vinculin monoclonal IgG mouse 1:6000 in Roti-Block
MeV N-Protein polyclonal IgG rabbit 1:6000 in 5% milk/TBS-Tween
SuperCD polyclonal IgG rat 1:2000 in Roti-Block
Mouse IgG polyclonal IgG, HRP-linked1 goat 1:30000 in Roti-Block
Rabbit IgG polyclonal IgG, HRP-linked1 goat 1:30000 in Roti-Block
Rat IgG polyclonal IgG, HRP-linked1 goat 1:30000 in Roti-Block
1 The secondary antibodies used are conjugated to horseradish peroxidase, which, utilizing hydrogen
peroxide, oxidizes luminol (which then exhibits chemiluminescence)
Luminol was activated by the horseradish peroxidase after incubation with both
luminol reagent and peroxide solution for 1 minute. An X-Ray film was used
for capturing the luminescence (Hyperfilm ECL) and developed immediately after-
wards.
2.9 SRB and LDH assays
The day before treatment, RBE, TFK-1, or HuCCT1 were plated in 24 well plates
(7.5× 104 cells/well in 0.5 ml culture medium). For the 5-fluorouracil treatment,
the medium was changed to a medium containing the adequate amount of 5-FU
after the cells were allowed to attach. For treatments involving viral infection, cells
were washed with PBS and infected with measles vaccine virus at varying MOIs
(the volume used for infection was 0.25 ml/well for 24 well plates) following the
procedure described in Section 2.6. Three hours post-infection (hpi), the infec-
tion medium was replaced with RPMI-1640 + 10% FBS containing the appropriate
amount of 5-FC.
After 96 hours, remaining cell mass was determined by Sulforhodamine B assay
and cell membrane damage was measured by the lactate dehydrogenase release as-
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say. For these assays, independent experiments were performed in quadruplicate
and repeated three times.
The Sulforhodamine B assay is an assay to determine remaining cell mass, after dif-
ferent treatments in an adherent cell culture [139]. SRB is a water-soluble red fluor-
escent dye, which binds electrostatically and pH-dependent onto basic amino acid
residues of cells fixed with trichloroacetic acid (TCA, C2HCl3O2).
Cells were washed with cold PBS (4 ◦C) twice, fixed in 10% TCA at 4 ◦C for 30
minutes, washed with tap water (four times) and dried for at least 12 hours. Then,
cells were covered with the SRB staining solution (0.04% Sulforhodamine B so-
dium salt and 1% TCA in H2O) for 10 minutes, washed repeatedly with 1% TCA to
remove unbound SRB dye and dried again. The dye was solubilized in 10 mM Tris
(adjusted to pH 10.5 with HCl) on ice. 80 µl of the solution was transferred into a
clear bottom 96 well plate and the optical density was measured at 550 nm in a
Tecan Genios plus microplate reader. Values were normalized to the untreated con-
trols for each experiment.
The lactate dehydrogenase (LDH) release assay can be used to indirectly measure
cell membrane damage after cytotoxic treatment [140, 141]. LDH is a stable cyto-
plasmic enzyme present in all cells. In this assay, LDH released from the treated
cells reduces pyruvate to lactate, while oxidizing NADH to NAD+. Photometric-
ally, NADH has an absorption maximum at 340 nm while the absorption of NAD+
at this wave length is negligible. The amount of released LDH in the sample is,
therefore, directly proportional to the the rate of decrease of NADH, which can be
measured easily in a microplate reader. To correctly determine the total amount of
LDH in each well (free and intracellularly) and allow calculation of the relative
LDH release, cells were lysed after measuring LDH in the supernatant and LDH re-
lease was determined again.
In this study, 10 µl of the supernatant were transferred into a clear bottom 96 well
plate. Then, 200 µl of the prepared working reagent were added to each well (con-
sisting of 80 mM Tris (adjusted to pH 7.5 with HCl), 200 mM NaCl, 1.6 mM Pyruvate
and 0.2 mM NADH+H+ at room temperature). The optical density was measured
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at 340 nm in a microplate reader five times, every two minutes. Afterwards, the su-
pernatant of each well was discarded and cells were lysed with 0.1% Triton X-100
in PBS (at 37 ◦C for 10 min). Then, LDH activity was measured in the lysate like-
wise. Relative LDH release was calculated by dividing the measured LDH activity
in the supernatant by the sum of the LDH activities in the supernatant and the lys-
ate.
2.10 Animal experiments
All animal experiments were conducted according to the German Animal Protec-
tion Act (Tierschutzgesetz) and were approved by the local authorities (Regierungs-
präsidium Tübingen). The experiments were registered as 35/9185.81-2 M6/09
(preliminary engrafment tests and MeV P-SCD vs TFK-1 in CanN.Cg-Foxn1nu/Crl
mice) and 35/9185.81-2 M6/11 (MeV ld-SCD vs HuCCT1 in Hsd:Atymic Nude-
Foxn1nu mice).
Mice were kept in isolated ventilated cages in rooms set at 22 ◦C with a 12
hours/12 hours dark-light cycle. Mouse handling, recordings, and injections
were performed in a laminar flow cabinet. Mice had free access to standard
chow and water. Mice were monitored three times per week for general health,
and their bodyweights were recorded. "Tumours were measured with a cal-
iper and tumour volume was calculated from the ellipsoid volume formula
(length x (width)2 x pi / 6) [142]. Animals were sacrificed when tumour volumes
reached 2000 mm3, weight loss over 20% of body weight occurred, or a rel-
evant change in behaviour or ulcerating tumours were observed." [1] Anim-
als were sacrificied in carbon dioxide anaesthesia followed by cervical disloca-
tion.
In these in vivo experiments, RBE, TFK-1 or HuCCT1 cells (1× 107 cells in 100 µl
PBS) were injected subcutaneously into the right flank of four to six week old
female CanN.Cg-Foxn1nnu/Crl or Hsd:Atymic Nude-Foxn1nu mice on day 0 of
the experiments. Beforehand, cells were detached in 0.05% Trypsin-EDTA, then
washed with PBS and centrifuged (200 g for 15 min). Cells were injected with a 22
gauge needle without the need for anaesthesia.
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When tumours reached a volume of about 100 mm3, mice were randomized
(matched for tumour volume) into four treatment groups: vehicle control, vehicle
control + 5-FC, MeV and MeV + 5-FC. Then, mice received daily injections of
either MeV P-SCD (1× 106 pfu) or MeV ld-SCD (1× 107 pfu) in 100 µl Opti-MEM
intratumourally with a 27 gaugle needle (days 0-4, control groups received vehicle
medium only). From days 5-11, mice received seven intraperitoneal injections of
500 mg/kg of 5-fluorocytosine (control groups were not treated intraperitoneally).
5-FC was dissolved in 50 ◦C-warm PBS and ultrasound-treated until the solution
was clear. Until use, the solution was stored at 42 ◦C.
For comparison between two groups, the unpaired, two-tailed Student’s t-test was
used. The Log-rank test was used to calculate differences between survival curves.
It was specified before beginning of the experiments that the group sizes of mice
treated with vehicle control and 5-FC would be reduced compared to the other
groups and excluded from statistical analysis. Analysis was done with GraphPad
Prism 6.0f (GraphPad Software, San Diego, CA, USA). P-values less than 0.05 were
considered as statistically significant.

CHAPTER 3
RESULTS
The aim of this thesis was to evaluate the feasibility of using a suicide gene-armed
measles vaccine virus as a new form of treatment against cholangiocarcinoma.
First, the growth characteristics of different measles vaccine virus vectors in well-
defined cholangiocarcinoma cell lines were analysed through various methods
(Sections 3.2 to 3.5). Subsequently, the potential benefits of this vector-based
suicide gene therapy were explored in the same cholangiocarcinoma cell lines (Sec-
tions 3.6 and 3.7). Two mouse-based in vivo trials (Sections 3.8 to 3.10) concluded
the experiments.
3.1 CD46 is expressed on human cholangiocarcinoma cells
Measles vaccine virus uses CD46, an inhibitory complement receptor found on all
nucleated cells, to mediate cell entry. "Overexpression of CD46 has been shown to
be a prerequisite for the typical cytopathic effect of measles vaccine virus and thus
seems to play an important role in MeV-mediated oncolysis [92]." [1] Accordingly,
CD46 expression on human cholangiocarcinoma cell lines was determined by flow
cytometry analysis using a phycoerythrin-labelled antibody directed against CD46
(Section 2.4). "The minimum mean fluorescence index required for substantial
MeV-mediated oncolysis has been shown to be between 25 and 50 (compare Sec-
tion 1.5 and [92])." [1]
The mean fluorescence index of TFK-1 cells was detected at 139 ± 29 (mean
± SD), which was highest among the three cell lines; the indices of RBE, and
32
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HuCCT1 cells were 51 ± 14 and 36 ± 5, respectively. Thus, all three cholangiocar-
cinoma cell lines under investigation were found to express CD46 to an extent
theoretically sufficient to support infection by measles vaccine viruses (Figure 11).
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Figure 11. CD46 expression on human cholangiocarcinoma cell lines. Cells were
stained with a phycoerythrin-labelled anti-CD46 antibody (purple histogram) or an isotype
control (white histogram) and analysed by flow cytometry. Numbers represent the ratios of the
mean fluorescence index of the purple histogram:white histogram of three independent exper-
iments. Representative diagrams were chosen for each cell line from these three experiments.
Reproduced from [1].
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3.2 Cholangiocarcinoma cells are susceptible to MeV infection
To test for the susceptibility to measles vaccine virus, human cholangiocarcinoma
cell lines RBE, TFK-1, and HuCCT1 were infected with MeV P-DsRed and analysed
by phase contrast and fluorescence microscopy. The backbone of this MeV vector
was identical to the Schwarz vaccine strain. Additionally, an open reading frame
encoding for the SuperCD suicide gene was inserted into the genome at position 3
(compare Figure 10).
As a result, all human cholangiocarcinoma cell lines were found to be infected
with MeV P-DsRed successfully. "Syncytia formation, a fusion of infected cells
with neighbouring uninfected cells leading to the typical MeV-mediated cyto-
pathic effect, was observed in all three cell lines, although to different extents."
[1] These are marked by the expression of DsRed (e.g. in the lower right corner
of Figure 12, in which a syncytium consisting of roughly 8-10 cells can be identi-
fied)
Former syncytia can be identified by loss of cell border and an increased number of
condensed nuclei (compare the left panel of Figure 12, marked by an arrow). Often,
these syncytia are detached from the well bottom and only cell debris remains
locally. The corresponding areas in the fluorescence image are dark as an indication
that cell integrity of the host cells is lost.
Microscopy	RBE	MOI	0.01	72h	
200	µm	
Figure 12. Phase contrast and fluorescence microscopy of syncytia formation in RBE
cells 72 hours after infection with MeV P-DsRed. Cells were infected with MeV P-DsRed
at an MOI of 0.01, and pictures were taken at three days post-infection. Depicted is a phase
contrast (left) and fluorescence (right) image of the same well area. The arrow points to a
former syncytia. The scale bar (200 µm) in the left panel applies to both panels.
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Microscopy 48h
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RBE
1000 µm
Figure 13. Phase contrast and fluorescence microscopy of human cholangiocar-
cinoma cells 48 hours after infection with MeV P-DsRed. Cells were infected with MeV
P-DsRed at MOI 1, and pictures were taken after two days. Panels show phase contrast (left)
and fluorescence (right) pictures. The scale bar (1000 µm) in the top left panel applies to all
panels. Reproduced from [1].
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control MeV P‐DsRed (MOI 1)
Figure 14. Phase contrast and fluorescence microscopy of human cholangiocar-
cinoma cells 96 hours after infection with MeV P-DsRed. Cells were infected with MeV
P-DsRed at MOI 1, and pictures were taken after four days. Panels show phase contrast (left)
and flourescence (right). The scale bar (1000 µm) in the top left panel applies to all panels.
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"After 48 hours, the cytopathic effect of MeV was found to be most profound in
TFK-1 cells and was slightly weaker in RBE cells. In contrast, infection of HuCCT1
cells only showed a low-grade infection with limited formation of syncytia (Fig-
ure 13)." [1]
96 hours after infection, the cell layers of both RBE and TFK-1 were almost com-
pletely eliminated (Figure 14). In contrast, the HuCCT1 cultures shows a large
amount of dead cells, that have detached from the well bottom, while the cell layer
is still intact and adherend to the well bottom. At 96 hours after infection, all three
cell lines show a decreased fluorescence signal compared with Figure 13, which
was taken after 48 hours.
3.3 Measles vaccine virus infection leads to transgene expression
Expression of virus-encoded proteins was confirmed by Western blotting in all
three human cholangiocarcinoma cell lines (Section 2.8). In this experiment, human
vinculin was used as the loading control and detected at 116 kDa. Both measles vac-
cine virus nucleoprotein and the SuperCD transgene could be detected at their ex-
pected molecular weights of 58 kDa and 42 kDa, respectively (Figure 15). "HuCCT1
cells showed a weaker expression of virus-encoded proteins, which was in line
with the weaker DsRed expression and the less-pronounced cytopathic effect ob-
served previously." [1]
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Figure 15. Detection of MeV nucleoprotein and SuperCD in MeV-infected cells. Cells
were mock-infected (lanes 1-3) or infected with either MeV P-DsRed (lanes 4-6) or MeV
P-SCD (lanes 7-9) at an MOI of 0.1 and harvested 54 hours later. Immunoblotting was
performed by employing antibodies against human vinculin (top panel at 116 kDa), measles
vaccine virus nucleoprotein (middle panel at 58 kDa), or SuperCD (bottom panel at 42 kDa).
Reproduced from [1].
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3.4 Differences of MeV replication in cholangiocarcinoma cells
"In order to quantify replication of oncolytic MeV, viral growth curves were per-
formed (Figure 16). MeV P-DsRed replicated efficiently in all three cell lines." [1]
Overall, in two out of three cell lines (RBE and TFK-1) and until 96 hours after
infection (the last time point in this experiment), more viral particles remained cell-
associated than released into the supernatant.
Between 24 and 48 hours, viral titers determined from both supernatant and RBE
cells directly rose significantly faster compared with both TFK-1 and HuCCT1 cells
and only reached their peak at 96 hours (6.3× 105 pfu/ml). In TFK-1 cells, the
number of cell-associated MeV particles reached a plateau as early as 48 hours after
infection (0.45× 105 pfu/ml), "presumably due to viral oncolysis already causing
profound cell death at this time point (as observed in Figure 13). Replication in
HuCCT1 cells appeared to be slower compared with RBE and TFK-1 cells, an obser-
vation consistent with the weaker transgene expression observed by immunoblot-
ting and microscopy (Figures 13 and 15)." [1]
3.5 Measles vaccine virus spreads rapidly in cell culture
After quantifying the absolute number of infectious particles produced, the rate of
infection was assessed by counting the number of DsRed-positive cells by flow
cytometry (Section 2.4).
Transgene expression after MeV infection started during the first 24 hours post-
infection (see Figure 17). Similar to the preceding experiments, RBE cells were
very permissive to infection, and DsRed was expressed in a majority of cells after
24 hours and reached its maximum after 48 hours. Mirroring the results obtained
previously (Section 3.4), the maximal amount of TFK-1 cells infected was already
reached after 48 hours post-infection. This can be explained by a high susceptibility
of TFK-1 to viral oncolysis leading to cell death and thereby to a decrease in virus
production and subsequently further spread. In HuCCT1 cells, a multiplicity of in-
fection of 1 was needed for an infection of a meaningful number of tumour cells (>
20%) cells, starting at 48 hours.
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Figure 16. Replication of MeV P-DsRed in human cholangiocarcinoma cell lines. Cells
were infected with MeV P-DsRed at MOI 0.1. Cells (black) and supernatant (purple) were
harvested daily over four days, and viral titers were determined on Vero cells. Values represent
mean ± SEM from three independent experiments performed in quadruplicate and plotted on
a semilogarithmic plot. Reproduced from [1].
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Figure 17. Rate of infection of human cholangiocarcinoma cell lines by MeV P-DsRed.
Cells were infected with MeV P-DsRed at various MOIs, ranging from 0.01 to 1. Daily for three
days, cells were analysed by flow cytometry to determine the percentage of DsRed-positive
cells. Values represent mean ± SD from three independent experiments.
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3.6 Toxification of the 5-FC prodrug impairs tumour cell growth
"Sensitivity to the activated form of the prodrug is a prerequisite for efficient sui-
cide gene therapy" [1], which in the case of the SuperCD suicide transgene catalyses
the intracellular conversion of 5-fluorocytosine to 5-fluorouracil. Therefore, the
effects of 5-FU on the selected human cholangiocarcinoma cell lines were investig-
ated by a Sulforhodamine B cell mass assay (Figure 18).
Concentrations of 0.01 − 0.1 mM 5-FU were found to reduce the tumour cell mass
in all cell lines to 50% of the control, with an almost complete cell killing at 1 mM.
More specifically, the mean remaining tumour cell mass after four days of treat-
ment with 1 mM 5-FU was 17.9% for RBE (IC50 0.0049 mM), 4.8% for TFK-1 (IC50
0.0539 mM), and 7.7% for HuCCT1 cells (IC50 0.0116 mM).
3.7 Therapy with suicide gene-armed MeV vectors and prodrug ap-
plication efficiently reduces cell survival
"In order to assess both virus-mediated oncolysis alone and cytotoxicity induced
by the combination therapy, the effects of a range of MOIs and concentrations of 5-
fluorocytosine were tested via the Sulforhodamine B cell mass assay and also a lact-
ate dehydrogenase release assays (Section 2.9)." [1]
"MeV P-SCD proved to be highly cytotoxic in TFK-1 cells (Figure 19, middle panel).
At an MOI of 1, even without the addition of 5-FC, 90% of the cells were killed
after 96 hours. A similar effect was observed in RBE cells, where approximately
70% of the cells were killed at an MOI of 1. In both cell lines, the addition of the
prodrug 5-FC led to a significantly enhanced cytotoxicity: For example, cell death
after infection at MOI 0.1 was significantly enhanced by the addition of 1 mM
5-FC in RBE cells from 85.5% to a mean remaining cell mass of only 18.3%, and in
TFK-1 cells from 69.8% to 2.7% mean remaining cell mass (Figure 19). These obser-
vations were confirmed in lactate dehydrogenase release assays that correlated
closely with the rates of cell mass reduction measured in the SRB assay (Figure 20)."
[1]
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Figure 18. Cytotoxic effect of 5-fluorouracil on RBE, TFK-1, and HuCCT1. Cells were
treated with various concentrations of 5-FU for four days. Cell mass was measured in a
Sulforhodamine B assay. Values were normalised to the untreated control and represent
mean ± SEM from three independent experiments performed in quadruplicate and plotted on
a semilogarithmic plot. Reproduced from [1].
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"However, in HuCCT1 cells, where viral replication was less pronounced than
in the other two cell lines, even an MOI of 1 was found to be not sufficient to
induce a significant tumour cell killing. Importantly, by addition of 5-FC, this
low susceptibility to MeV-mediated oncolysis was overcome and cell survival
was found to be significantly reduced: from 87.8% (MeV P-SCD at an MOI of 1)
to 4.4% remaining cell mass (MeV P-SCD at an MOI of 1 plus 1 mM 5-FC)," [1]
indicating the high effectivity of the SuperCD transgene especially in the con-
text of low replication of virotherapeutic vectors in distinct tumour cell types.
This large-scale increase in cytotoxicity was confirmed in the LDH release assay.
To test whether the transgene position of SuperCD influenced direct cell death by
the measles virus as well as the enhanced oncolytic effect after prodrug application,
SRB assays using MeV ld-SCD under the same conditions were performed addi-
tionally (Figure 21). The genomic backbone of MeV ld-SCD is identical to MeV P-
DsRed, however the SuperCD transgene is positioned at genome position 1 instead
of genome position 3 (compare Figure 10).
Examining cell death after MeV infection alone, the remaining cell mass after
infection with MeV P-SCD at both MOI 0.1 and 1 was lower in RBE and TFK-1, but
not in HuCCT1 cells, compared with MeV ld-SCD. However, when the prodrug
5-fluorocytosine was added, cell mass was markedly decreased in all cells treated
with MeV ld-SCD. The most profound difference between the two viruses was
found in the HuCCT1 cell line, where remaining cell mass after treatment with
MeV ld-SCD (MOI 0.1 plus 1 mM 5-FC) was at only 9.9% compared with 35.3%
after treatment with MeV P-SCD. Please refer to Table 4 for a detailed compar-
ison.
These results indicate, that the position of the SuperCD transgene exerts a direct in-
fluence on the rate of tumour cell killing. Here, the leader position of the transgene
was found to be significantly superior regarding tumour cell death in comparison
to positioning the SuperCD transgene between the P and M protein open reading
frames.
Results 43 In vitro MeV/Prodrug Evaluation
RBE
0
0
25
50
75
100
1E‐04 1E‐03 1E‐02 1E‐01 1E‐00
control
MOI 1
MOI 0.1
MOI 0.01
5‐FC (mM)
ce
ll m
as
s (
%
 co
nt
ro
l)
0
0
25
50
75
100
1E‐04 1E‐03 1E‐02 1E‐01 1E‐00
control
MOI 1MOI 0.1
MOI 0.01
5‐FC (mM)
ce
ll m
as
s (%
 co
nt
ro
l)
TFK‐1
0
0
25
50
75
100
1E‐04 1E‐03 1E‐02 1E‐01 1E‐00
control
MOI 1
MOI 0.1
MOI 0.01
5‐FC (mM)
ce
ll m
as
s (%
 co
nt
ro
l)
HuCCT1
Figure 19. Cytotoxic effects of MeV P-SCD + 5-fluorocytosine. Cells were infected with
MeV P-SCD at MOIs 0.01, 0.1 and 1, and incubated with varying concentrations of 5-FC
for four days. Remaining cell mass was measured in a Sulforhodamine B assay. Values
were normalised to the untreated control and represent mean ± SEM from three independent
experiments performed in quadruplicate and plotted on a semilogarithmic plot. Reproduced
from [1].
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Figure 20. Effects of MeV P-SCD + 5-fluorocytosine. "Cells were infected with MeV P-
SCD at MOIs 0.01, 0.1, and 1 and incubated with varying concentrations of 5-FC for four
days. Cytotoxicity was measured in a lactate dehydrogenase release assay. Values represent
the mean ratio between LDH in the supernatant and the total LDH measured in each well
± SEM from three independent experiments performed in quadruplicate and plotted on a
semilogarithmic plot." [1] Reproduced from [1].
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Figure 21. Cytotoxic effects of MeV ld-SCD + 5-fluorocytosine in human cholangiocar-
cinoma cell lines. Cells were infected with MeV ld-SCD at MOIs 0.01, 0.1, and 1 and
incubated with varying concentrations of 5-FC for four days. Cell mass was measured in a
Sulforhodamine B cytotoxicity assay. Values were normalised to the untreated control and
represent mean ± SEM from three independent experiments performed in quadruplicate and
plotted on a semilogarithmic plot.
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Table 4. Oncolytic capacity of MeV P-SCD and MeV ld-SCD in comparison. Cells were
infected with MeV P-SCD or MeV ld-SCD (MOI of 0.1 or 1) only or treated additionally with
1 mM 5-fluorocytosine starting three hours post-infection. Values were taken from Figure 19
and Figure 21 and represent remaining cell mass in percent of the control.
MOI 0.1 MOI 0.1 + 5-FC MOI 1 MOI 1 + 5-FC
RBE
MeV P-SCD 85.5 18.3 32.5 2.3
MeV ld-SCD 84.9 15.5 43.0 3.0
TFK-1
MeV P-SCD 69.8 2.7 9.9 1.7
MeV ld-SCD 60.6 5.4 13.8 2.2
HuCCT1
MeV P-SCD 97.0 35.3 87.8 4.4
MeV ld-SCD 82.8 9.9 56.2 2.1
3.8 TFK-1 and HuCCT1 cells successfully engraft in nude mice
Before assessing the efficacy of the armed measles vaccine virus vectors in vivo, we
established different human cholangiocarcinoma xenograft models in nude mice.
For this, RBE, TFK-1, or HuCCT1 cells were used to establish subcutaneous human
tumours in nude mice (Section 2.10).
TFK-1 and HuCCT1 cells successfully engrafted in 7/10 and 10/10 animals, re-
spectively. No animals injected with RBE cells developed a tumour until the experi-
ment was ended after 61 days of monitoring. An overview of the successful engraft-
ments in all in vivo experiments can be found in Table 5.
Tumour volumes for TFK-1 and HuCCT1 were measured three times weekly and
are shown in Figure 22.
Table 5. Comparison of successful tumour engraftments of different human cholan-
giocarcinoma cell lines in nude mice. This table summarises the successfully engrafted
tumours (defined as tumour volume larger than 100 mm3) from the experiments in Sections 3.8
to 3.10.
Preliminary
Tests
MeV Trials Overall Success
RBE 0/10 – 0%
TFK-1 7/10 31/35 84%
HuCCT1 9/10 41/42 96%
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HuCCT1	
Figure 22. Tumour volumes of nude mice after implantation with TFK-1 or HuCCT1
human cholangiocarcinoma cells. 1× 107 human cholangiocarcinoma cells were injected
into the flank of nude mice in order to establish a xenograft tumour. Tumour volumes were
measured until the experiment was ended at a predetermined time point. Each individual
tumour is plotted (grey lines) as well as the mean tumour volume on each day (blue line).
3.9 Suicide-gene armed MeV virotherapeutic vectors reduce tumour
growth in TFK-1 xenografts
For the first of two in vivo experiments, MeV P-SCD was tested in a TFK-1 xeno-
graft mouse model. Tumours were established by the protocol defined earlier
(Sections 2.10 and 3.8). "When tumours reached a volume of approximately
100 mm3, mice were randomised into four treatment groups: vehicle control (9
mice), vehicle control + 5-fluorocytosine (7 mice), MeV P-SCD only (7 mice),
and MeV P-SCD + 5-fluorocytosine (7 mice)." [1] Mice were intratumourally in-
jected for five consecutive days with MeV P-SCD or vehicle control, followed
by seven days of intraperitoneal treatment with 5-FC for mice randomised to
the prodrug cohorts. Mean tumour volume for each group is plotted in Fig-
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ure 23. The experiment was ended 200 days after tumour implantation (173
days and 130 days after start of treatment for the first and last batch respect-
ively).
"Treatment with virus and prodrug significantly inhibited tumour growth com-
pared with the untreated control (p=0.03 at day 46), while MeV P-SCD without
the addition of 5-FC did not significantly influence tumour growth compared
with the control group. 46 days after initiation of treatment (Figure 24), mean
tumour volume of mice treated with the combination therapy were found to be
smaller (380 mm3) than the mean tumour volume of mice treated with MeV P-
SCD only (637 mm3); however, this difference was not statistically significant."
[1]
"Tumours from all treatment groups (including the control group) developed
central tumour necrosis starting at approximately day 80 after tumour implanta-
tion. In most cases, this led to the development of necrotic cysts, which interfered
with tumour volume measurements. Therefore, long-term tumour volume meas-
urements were not feasible, and thus survival of mice could not be evaluated."
[1]
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Figure 23. Antitumour effect of MeV P-SCD + 5-fluorocytosine in a TFK-1 human
cholangiocarcinoma xenograft mouse model. When tumours reached a volume of ap-
proximately 100 mm3, mice were randomised into four treatment groups: vehicle control (9
mice), vehicle control + 5-FC (7 mice), MeV P-SCD only (7 mice), and MeV P-SCD + 5-FC (7
mice). Mice were treated daily for five days with intratumoural injections of MeV P-SCD or
vehicle control, followed by seven injections of 5-FC intraperitoneally (one per day). Mean
tumour volume for each group ± SEM is plotted until the first animal of each group had to be
sacrificed. Reproduced from [1].
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Figure 24. Individual tumour volumes of mice with TFK-1 xenograft tumours treated
with MeV P-SCD + 5-fluorocytosine and corresponding controls at start of treatment
and on day 46. Experimental setup is detailed in Figure 23. Tumour volumes for day 46 after
start of treatment are plotted (this is the last day on which all mice from all treatment groups
survived). When comparing groups with the Student’s t-test, only the difference of tumour
volumes between vehicle control (vehicle) and MeV P-SCD + 5-FC (MeV + 5-FC) can be
considered statistically significant (p=0.03). Reproduced from [1].
3.10 Treatment with MeV prolongs survival in HuCCT1 xenografts
"We conducted a second in vivo experiment, now using the HuCCT1 cell line for
which a lower susceptibility to MeV-mediated oncolysis was shown earlier in vitro
(Section 3.7). HuCCT1 tumour-bearing mice were treated with the same schedule
as described above. To further enhance the anti-tumour effect, MeV ld-SCD, in
which the SuperCD transgene is expressed from genome position 1 instead of
position 3 (Figure 21), was employed. This virus had demonstrated enhanced
oncolytic efficacy in comparison with MeV P-SCD in vitro, both in the virus-only
setting as well as in combination with the prodrug (as described in Section 3.7)."
[1]
"Tumours from both virus-treated groups were found to regress in the course of
oncolytic treatment, but slightly reinitiated their growth from day 30 onward (Fig-
ure 25). Mean tumour volumes after 48 days (Figure 26) were significantly larger
in the control group (658 mm3) than in groups treated with MeV ld-SCD, both
with and without the addition of 5-FC (124 mm3, p=0.0008 and 42 mm3, p<0.0001
respectively). Tumour volume was slightly larger in the MeV ld-SCD + 5-FC group
compared with MeV ld-SCD only; however, this difference was not statistically sig-
nificant." [1]
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Figure 25. Antitumour effect of MeV ld-SCD + 5-fluorocytosine in a HuCCT1 human
cholangiocarcinoma xenograft mouse model. When tumours reached a volume of ap-
proximately 100 mm3, mice were randomised into four treatment groups: vehicle control (12
mice), vehicle control + 5-FC (5 mice), MeV ld-SCD only (12 mice), and MeV ld-SCD + 5-FC
(12 mice). Mice were treated daily for five days with intratumoural injections of MeV ld-SCD or
vehicle control, followed by seven injections of 5-FC intraperitoneally (one per day). Mean
tumour volume for each group ± SEM is plotted until the first animal of each group had to be
sacrificed. Reproduced from [1].
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Figure 26. Individual tumour volumes of mice with HuCCT1 xenograft tumours treated
with MeV ld-SCD + 5-fluorocytosine and corresponding controls at start of treatment
and on day 48. The experimental setup is detailed in Figure 25. Tumour volumes for day 48
after start of treatment are plotted (this is the last day on which all mice from all treatment
groups survived). When comparing groups with the Student’s t-test, the differences of tumour
volumes between vehicle control (vehicle) and MeV ld-SCD + 5-FC (MeV + 5-FC) as well as
between vehicle control (vehicle) and MeV ld-SCD only (MeV) can be considered statistically
significant (p=0.0008 and p<0.0001, respectively). Reproduced from [1].
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Differences in the survival curves (Figure 27) between the different treatment
groups were found: After 242 days, when the experiment was ended (timepoint
was determined before starting the experiment), survival was 0/12 animals
in the vehicle control group, 1/5 animals for vehicle control + 5-FC, 5/12 for
MeV ld-SCD only, and 4/12 for treatment with MeV ld-SCD + 5-FC. There
was a statistically significant survival benefit for mice treated with MeV ld-
SCD and 5-FC (median survival 93 days) or with MeV ld-SCD only (196 days)
compared with the untreated control (55 days; p=0.0097 and p=0.0002, respect-
ively).
All taken together, our armed MeV vectors showed similar efficacy in vivo as
in the cell culture experiments described in the beginning of the chapter. In
both experiments, tumor mass was significantly smaller in the animals treated
with the viruses. While survival could only be evaluated in one experiment,
there was a significant survival benefit for the animals treated with MeV ld-
SCD.
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Figure 27. Kaplan-Meier survival curves of mice treated with MeV ld-SCD in com-
bination with 5-fluorocytosine and corresponding controls. The experimental setup is
detailed in Figure 25. Survival curves significantly differed between mice treated with MeV
ld-SCD and 5-FC (median survival 93 days) or with MeV ld-SCD only (196 days) compared
with the untreated control (55 days; p=0.0097 and p=0.0002, respectively). The difference
between survival times of mice treated with MeV ld-SCD with or without the addition of 5-FC
was not significant. Reproduced from [1].
CHAPTER 4
DISCUSSION
"Diagnosis of cholangiocarcinoma usually takes place late in the course of the
disease, which either makes surgery not feasible or results in an incomplete
resection of the tumour. Therefore, novel therapies against advanced stage cholan-
giocarcinoma are urgently needed. A multitude of new biological compounds are
currently under development, involving e.g. targeted small molecules and immun-
otherapeutics. But so far, no significant, practice-changing improvement in treating
this fatal disease has been achieved [16]." [1]
4.1 CD46 expression varies between cholangiocarcinoma cell lines
In our study, we demonstrated that human cholangiocarcinoma cell lines express
the CD46 receptor (Section 3.1), which is the entry gateway for the measles vaccine
virus and is required for efficient MeV-mediated oncolysis. It had been shown
previously that the density of CD46 receptors on the cell membrane is important
for virus entry and syncytia formation [92]. In this respective study, the mean
fluorescence index was used as a surrogate marker for CD46 receptor density,
and a value between 25 and 50 was needed for substantial MeV-mediated onco-
lysis.
In our study, the CD46 receptor density was lowest on HuCCT1 cells (mean fluores-
cence index of 36), which in the following experiments proved to be the most resist-
ant to MeV oncolysis alone, i.e. without additional application of 5-FC. This correl-
ation between the cytopathic effect and CD46 expression was previously observed
by Berchtold et al. [143], as well. Here, MeV ld-SCD was tested against human
52
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sarcoma cell lines. Three cell lines were defined as ’primary resistant’ to oncolysis
(remaining cell mass > 50% after 96 hours as determined by SRB assay), and the
mean fluorescence index of CD46 was between 20 and 40 for these cells (lower than
the susceptible cell lines). In our study, HuCCT1 was the only cell line with a min-
imum mean fluorescence index < 50, and, under the criteria defined previously, is
the only ’primary resistant’ cell line exhibiting a ’primary resistance’ to infection by
MeV.
Nevertheless, low CD46 receptor density very likely does not constitute the only
mechanism of resistance to MeV oncolysis. This was demonstrated by Noll et al.
[144], where cell lines from solid tumours present in the well-characterised NCI-60
panel (a panel of 60 human tumour cell lines [145]) were screened systematically
for resistance to MeV ld-SCD oncolysis. Six cell lines were highly resistant to onco-
lysis (remaining cell mass > 75% after 96 hours as determined by SRB assay), but no
correlation to CD46 expression could be observed.
So far, the mechanisms of resistance to MeV infection and oncolysis have not been
unraveled in detail. What seems evident is that innate immunity, especially the
induction of an antiviral state of the host cell mediated by the interferon pathway
plays a major role in this phenomenon [94, 143].
4.2 Susceptible cell lines exhibit different growth characteristics
Evaluation of the cytopathic effect of MeV infection by light and fluorescence
microscopy revealed clear differences between the three cell lines (Section 3.2).
These differences in rates of primary infection and spread of MeV P-SCD were
reflected by all further in vitro experiments, as well (Sections 3.2, 3.4 and 3.5).
Overall, RBE and TFK-1 were consistently more susceptible to infection than
HuCCT1.
Infection of RBE cells with MeV P-DsRed was found to yield comparable amounts
of cell-bound and free virus to TFK-1 cells up until 48 hours post-infection. Then,
while the amount of virus produced still increases exponentially in RBE cells,
virus production in TFK-1 cells was found to slow down (resulting in a 100-fold
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difference in the amount of infectious viral particles being present at 96 hours (Sec-
tion 3.4)).
We believe that a combination of two factors is responsible for some of the differ-
ences observed in the two susceptible cell lines:
First, we found that, two days after infection with MeV P-SCD at an MOI of 1 (Fig-
ure 13), a large number of TFK-1 cells had already detached from the well bottom,
indicating an early loss of plasma membrane integrity. Additionally, in the cytotox-
icity assays, MeV P-SCD caused an increased oncolytic effect in TFK-1 cells com-
pared with RBE cells at all virus concentrations. This pronounced cytopathic effect
of the virus on TFK-1 cells leads to a substantial cell death at 48 hpi which decreases
virus production.
Second, direct cell-cell contact is a prerequesite for syncytia formation, which is im-
peded in TFK-1 cells: RBE cells form an adherend monolayer during the exponen-
tial growth phase covering the complete well bottom when allowed sufficient time
to grow. In contrast, TFK-1 cells, even several days after seeding, form patches of
cells without complete floor coverage (please refer to Figure 9 for light microscopy
images). An indirect method of evaluating the rate of syncytia formation is compar-
ing the rate of increase in DsRed-positive cells (Figure 17) after infection with a very
small amount of DsRed-encoding virus (i.e. MOI 0.01). After 48 hours, the percent-
age of DsRed-positive cells is negligible in both cell lines; however, after 72 hours,
the difference is significant: 45% of RBE cells and 7% of TFK-1 cells express DsRed
(compare Figure 17).
4.3 Resistance to MeV oncolysis can be overcome by prodrug-mediated
activation of the MeV-encoded SuperCD suicide gene function
As described in the previous section, HuCCT1 cells were more resistant to MeV
infection and oncolysis than RBE and TFK-1, which were described in the previ-
ous section. After infection with MeV P-SCD at an MOI of 1, HuCCT1 cell mass
remained at 88% of the control after four days, which was significantly higher than
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for RBE (32%) and TFK-1 (10%) cells. This might be an effect of lower CD46 ex-
pression (as explained in Section 4.1) that leads to lower rates of primary infection
(Section 3.5) and reduced syncytia formation (Section 3.2). Therefore, this cell line
might best reflect the additional benefit of the suicide gene/prodrug combination,
as the other two cell lines were very susceptible to MeV oncolysis per se, thereby
prodiving ’not enough additional space’ for a significant further improvement of
tumour cell killing.
First, we tested the cytoxic effect of 5-fluorouracil (the intermediate reagent
produced by SuperCD) alone (Section 3.6). The first substantial changes in
cell mass occured at a concentration of 0.001 mM. In further experiments, we
found that the cell mass of all cholangiocarcinoma cell lines was reduced to less
than 20% of the control after four days at the maximal concentration of 1 mM 5-
FU.
It was shown earlier by our group [115] that prodrug conversion by MeV ld-SCD is
extremely efficient. In this study, hepatoma cells were infected with MeV ld-SCD at
an MOI of 0.01. Conversion of 1 mM 5-FC to 5-FU or a subsequent byproduct was
determined by reverse-phase high-performance liquid chromatography. Complete
conversion was achieved after 24 hours in Hep3B cells and after 48 hours in HepG2
cells (it was noted by the authors that ’HepG2 cells were found to be less sensitive
towards the virus’).
Before initiation of the experiments with our human cholangiocarcinoma cell lines,
we speculated that the combination of sensitivity to 5-FU alone as well as the rapid
conversion of the prodrug into its toxic form should substantially enhance cell
killing. Indeed, this hypothesis was found to be supported by the results of two dif-
ferent cytotoxicity assays (Figures 19 and 20, summarised in Table 4). The addition
of 1 mM 5-FC to HuCCT1 cells decreased the remaining cell mass after four days
from 88% to 4% of the control when infected with MeV P-SCD at MOI 1. Similarly,
treatment of MeV P-SCD-infected RBE and TFK-1 with 5-FC led to increased cyto-
toxicity.
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4.4 Armed MeV reduces tumour growth and prolongs survival in
mice
In vivo, we showed that the tumour volume of mice bearing TFK-1 tumours, treated
with MeV P-SCD in combination with 5-FC, was significantly reduced compared
to mock-treated controls. Unfortunately, survival in this model could not be evalu-
ated due to the development of necrosis in the tumours (Section 3.9).
"Survival of HuCCT1 tumour-bearing mice was significantly prolonged com-
pared with mock controls when treated with MeV ld-SCD alone or in combin-
ation with 5-FC (Section 3.10). However, in this tumour model, we did not
observe superior effects of the combination therapy compared with treatment
with virus alone. This missing enhancement of tumour cell killing when mak-
ing use of our suicide gene armament might have been due to several reasons:"
[1]
(1) "SuperCD-mediated conversion of 5-FC into 5-FU and toxic metabolites might
have been insufficient. However, when employing reverse-phase high-performance
liquid chromatography for a direct quantification of 5-FC conversion into newly
produced 5-FU, an almost complete conversion within 24 hours was measured in
vitro, even when concentrations up to 1 mM 5-FC were used (as described in Sec-
tion 4.3). Thus, we conclude that our 5-FC prodrug convertase SuperCD is strong
enough to produce sufficient levels of 5-FU in tumour cells, at least under in vitro
conditions."[1]
"Interestingly, in the context of a vaccinia virus-based expression of FCU1 (which is
100% identical to our SuperCD suicide gene), a maximum concentration of 5.5 ng
5-FU/mg tumour tissue has been observed at 3-8 days post-infection in xenograft
human colon carcinoma tumours at one hour after daily single oral dosing of
100 mg/kg 5-FC [146]. This local concentration of 5-FU was calculated as being 20
times higher than the 5-FU concentrations being achieved when applying 5-FU sys-
temically under the conditions of standard chemotherapy protocols. Thus, there is
strong evidence that SuperCD/FCU1 constitutes a highly effective system for the
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intratumoural conversion of 5-FC into 5-FU under both in vitro and in vivo condi-
tions." [1]
This confirms earlier studies by Pederson et al. and Stackhouse et. al.: Here,
SK-ChA-1 cholangiocarcinoma cells were transduced with an adenovirus vector
encoding E. coli cytosine deaminase and successfully treated with 5-FC [116, 117].
Aditionally, Kojima et al. showed that infection of HuCCT1 cells with an ad-
enovirus expressing uracil phosphoribosyltransferase enhances cytotoxicity of 5-FU
[118].
(2) "In principle, there might also be a basal inability of 5-FU to kill tumour cells
of human cholangiocarcinoma origin. However, when we directly incubated our
selected human cholangiocarcinoma cell lines with 5-FU, concentrations as low
as 0.1 - 0.01 mM 5-FU were found to reduce the tumour cell mass in all three
cell lines to 50% of the control. Furthermore, an almost complete cell killing
was achieved at a concentration of 1 mM 5-FU (Section 4.3). These results were
found to be quite comparable with the results that were achieved in human hep-
atoma cell lines by Lampe et al., being also of primary liver origin [115]. Thus,
we conclude that 5-FU is functionally active in human cholangiocarcinomas."
[1]
(3) "Dosing of 5-FC might have been suboptimal under our current regime ap-
plying a 5-FC standard dose of 500 mg/kg body weight, which is quite often
used in mouse xenograft tumour models [147, 148]. However, in a recent pre-
clinical study, animal groups treated with adenovirus-based vectors (Ad-FCU1)
exhibited statistically significant differences in tumour sizes between the group
treated with Ad-FCU1 plus 5-FC and the other groups only when 5-FC was
given at 1,000 mg/kg body weight per day. Specifically, at 500 and 200 mg/kg
body weight per day, no effects of the suicide gene therapy were observed [146]."
[1]
"Therefore, one other explanation for our failure to reproduce the effects ob-
served in vitro of our prototypic MeV-based virotherapeutic MeV ld-SCD in the
HuCCT1 xenograft mouse model could be an underdosing of the 5-FC prod-
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rug: 1,000 mg/kg body weight per day could potentially be much more effective
than 500 mg/kg body weight per day. However, this should only be true if this
high-dose regimen would not be not accompanied by a 5-FC-based systemic
toxicity which already has been described for this dosing in a prior study [149]."
[1]
(4) "Timing of 5-FC prodrug application might have been suboptimal under our
current regime, starting with the 5-FC application after only five days of con-
secutive vector application. This procedure was inferred from the postulate
that early prodrug administration potentially leads to an early abrogation of
virus replication [96, 97, 150, 151]. This is supported by the results of a recent
systematic dissection of which specific timing of prodrug addition would be
optimal in a human xenograft setting when making use of a vector-encoded
suicide gene by systemic application of a respective prodrug:" [1] when using
a replication-conditional HSV-1-based virotherapeutic vector expressing yeast
cytosine deaminase, it was observed that 5-FC administration on the day of peak
viral replication (three days after intratumoural infection) led to a greater tumour
cell killing than any earlier or later 5-FC administration both in vitro and in vivo
[152].
Ungerechts et al. showed that the optimal treatment schedule for the same vector
(a CD20-targeted measles vaccine virus armed with Escherichia coli purine nucleoside
phosphorylase) differs greatly in two similar tumour models (non-Hodgkin’s lymph-
oma and mantle cell lymphoma) [96, 97].
"In general, the optimal time point for prodrug administration might be when virus
replication is at its peak. However, it seems very likely that different treatment
schedules have to be developed for each combination of tumour entity, virus and
encoded suicide gene(s). Pinpointing the exact moment of peak virus replication in
each and every tumour patient would require vector-encoded tracking tools (e.g.,
soluble marker proteins such as carcinoembryonic antigen [153] or membrane
channel proteins such as sodium-iodide-symporter [154]) that would enable the re-
petitive monitoring of virus replication and gene expression in a non-invasive man-
ner." [1]
Discussion 59 In Vivo Validation
In our study, we did not measure the viral growth kinetics in vivo and based
our schedule on older studies employing measles vaccine virus. However, these
viruses were not armed with SuperCD. In 2012, after completion of our experi-
ments, Zaoui et al. investigated the treatment of head and neck squamous cell
carcinoma with an EGFR-targeted oncolytic measles virus expressing both E.
coli cytosine deaminase and uracil phosphoribosyltransferase [107]. In a xenograft
mouse model, the researchers injected the vector intratumourally for five con-
secutive days and, two days after the last virus injection, started treatment with
5-FC intraperitoneally, following a similar schedule to our study with good effic-
acy.
"Another aspect is that long-term MeV replication in human xenograft tumours has
been observed previously [115, 153]. In these animals, repeated administration of
the prodrug alone might be beneficial, whereas in other animals exhibiting continu-
ous tumour growth with no signs of ongoing viral replication, additional cycles of
virus plus optimised administration of the respective prodrug might be required
to cause late-stage tumour regressions. It is of interest that repeated cycling has
already been applied successfully for MeV in the treatment of xenograft lympho-
mas [97]." [1]
"In our preliminary in vitro experiments (data not shown), we found that an early
administration of 5-FC (i.e., already at 3 hpi) yields much better results in terms
of oncolytic efficiency than any later administration (i.e. at 24 - 72 hpi)." [1] How-
ever, other studies from our group showed that delayed addition of the prodrug
enhances the overall effect on tumour mass in some cell lines as well: Lampe et
al. determined that 48 hours-post infection was the most efficient time point in
the Hep3B hepatoma cell line, yet not superior in two other hepatoma cell lines
(PLC/PRF/5 and HepG2) [115].
Another work from our group aimed to further optimise prodrug delivery [155].
Importantly, this study showed that the major determinant of cell mass reduction
by SuperCD-armed MeV and 5-FC is not the time span between infection and prod-
rug addition, but the overall time span in which 5-FC (and subsequently 5-FU) is al-
lowed to take effect on the tumour cells.
CHAPTER 5
SUMMARY
"Cholangiocarcinoma is curable only in its early stages by complete surgical resec-
tion. Thus, in advanced disease stages in which a complete removal of the tumour
mass is no longer possible and palliative chemotherapy only achieves modest
success, therapeutics employing new methods of action are needed. Oncolytic
viruses employed in clinical studies have been shown to preferentially infect can-
cer cells. Beyond that, virotherapeutic cell killing can be enhanced by virus-based
expression of suicide genes that convert non-toxic prodrugs into toxic reagents."
[1]
The aim of this thesis was to evaluate an oncolytic measles vaccine virus expressing
SuperCD, a fusion protein of yeast cytosine deaminase and yeast uracil phosphori-
bosyltransferase that converts the prodrug 5-fluorocytosine to 5-fluorouracil, an ap-
proved chemotherapeutic. This vector was evaluated using three different human
cholangiocarcinoma cell lines.
"In vitro, all cholangiocarcinoma cell lines were found to be permissive to MeV
infection. Partial blocking of MeV-mediated oncolysis could be overcome by
utilisation of the SuperCD transgene together with administration of the prodrug 5-
fluorocytosine." [1]
In vivo, intratumoural application of SuperCD-armed measles vaccine virus to-
gether with a systemic 5-fluorocytosine treatment showed a significant reduc-
tion in tumour size in a TFK-1 xenograft mouse model when compared with
virus-only treatment. In a second animal experiment employing a HuCCT1
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xenograft tumour model, an enhanced SuperCD-armed MeV vector, in which
the SuperCD transgene was expressed from a different genomic position, not
only led to reduced tumour volumes, but also to a significant survival bene-
fit.
These highly interesting results pave the way to a first phase I trial employing our
virotherapeutic vector (MeV ld-SCD) plus oral application of 5-FC in patients with
advanced, non-resectable cholangiocarcinoma.
CHAPTER 6
MATERIALS
6.1 Consumables
Caliper 150 mm Brüder Mannesmann
Cell scrapers Corning
Centrifuge tubes 15/50 ml Corning
Combitips 1/5/10/50 ml Eppendorf
Cryogenic vials, internal thread Corning
Decosept AF Dr. Schumacher
Filter tips 10/100/200/1000 µl Biozym Scientific
Forceps Servoprax
Hybond-P Amersham Biosciences
Hyperfilm ECL Amersham Biosciences
Microtiter plates 96 well Greiner Bio-One
Needles 27G/22G BD Medical
Pasteur Pipettes Wilhelm Ulbrich
Photo Film Fujifilm
Pipet tips 10/200/1000 µl Carl Roth
Round bottom tubes 14 ml Corning
Safe-lock reaction tubes 0.5/1/2 ml Eppendorf
Safe-lock reaction tubes, amber, 1.5/2 ml Eppendorf
Scalpels B. Braun
Sekusept plus ecolab
Serological pipettes 1/2/5/10/25/50 ml Corning
Syringes 1/10 ml B. Braun
Tissue culture dishes 10 cm Corning
Tissue culture dishes 6/15 cm Corning
Tissue culture flasks 25/75/175 cm2 Corning
Tissue culture plates 6/12/24/48/96 well Corning
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6.2 Reagents
5-Fluorocytosine Sigma-Aldrich
5-Fluorouracil Sigma-Aldrich
0.1% Triton X-100 Carl Roth
Accutase Innovative Cell Technologies
Acrylamid Rotiphorese Gel 30 Carl Roth
Bradford dye reagent Bio-Rad
Dimethyl sulfoxide Carl Roth
DMEM Sigma-Aldrich
Phosphate-buffered saline PAA Laboratories
Fetal bovine serum PAA Laboratories
Formaldehyd Carl Roth
Full Range Rainbow Protein Marker Amersham Biosciences
Isopropanol Merck
LDH P-mono Analyticon Biotechnologies
MycoTOOL PCR Mycoplasma Roche
Nonidet-P40 Carl Roth
Opti-MEM Gibco
Rotiblock Carl Roth
Roti Load Puffer Carl Roth
RPMI-1640 PAA Laboratories
Sulforhodamine B Sigma-Aldrich
Tris Carl Roth
Trypsin-EDTA (0.05%) PAA Laboratories
Tween 20 Promega
6.3 Animals
CanN.Cg-Foxn1nnu/Crl mice Charles River Laboratories
Hsd:Atymic Nude-Foxn1nu mice Harlan Laboratories
6.4 Manufacturers
Amersham Biosciences/GE Healthcare München, Germany
Analyticon Biotechnologies Lichtenfels, Germany
BD Medical Heidelberg, Germany
Bio-Rad München, Germany
Biozym Scientific Hessisch Oldendorf, Germany
B. Braun Melsungen, Germany
Carl Roth Karlsruhe, Germany
Materials 64 Manufacturers
Charles River Laboratories Sulzfeld, Germany
Corning Wiesbaden, Germany
Dr. Schumacher Melsungen, Germany
ecolab Monheim am Rhein, Germany
Eppendorf Wesseling-Berzdorf, Germany
Fujifilm Düsseldorf, Germany
Gibco/Thermo Fischer Waltham, MA, USA
Greiner Bio-One Frickenhausen, Germany
Harlan Laboratories Venray, Netherlands
Innovative Cell Technologies San Diego, CA, USA
Brüder Mannesmann Remscheid, Germany
Merck Darmstadt, Germany
Millipore Schwalbach, Germany
PAA Laboratories Pasching, Austria
Promega Mannheim, Germany
Roche Basel, Switzerland
Servoprax Wesel, Germany
Sigma-Aldrich München, Germany
Systec Wettenberg, Germany
Wilhelm Ulbrich Bamberg, Germany
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ZUSAMMENFASSUNG
Die einzige kurative Therapie des Cholangiokarzinoms besteht in einer chir-
urgischen Resektion in einem frühen Stadium. In fortgeschrittenen Stadien, in
welchen eine chirurgische Resektion des Tumors nicht mehr möglich ist und
etablierte palliative Chemotherapie-Regime wenig Linderung und nur eine ge-
ringe Lebensverlängerung erzielen, werden dringlich neuartige Therapieansät-
ze benötigt. In klinischen Studien wurde gezeigt, dass sich onkoloytische Vi-
ren vorzugsweise in Krebszellen ausbreiten. Darüber hinaus kann dieser viro-
therapeutische Effekt durch eine Suizidgentherapie verstärkt werden. Hierbei
werden durch Enzyme, welche im Virusgenom kodiert sind, inaktive Medika-
mentenvorstufen in aktive Metabolite mit starker antitumoraler Wirkung über-
führt.
Ziel dieser Doktorarbeit war die Evaluierung zweier neuartiger Masern-Impfviren,
welche für eine Super-Cytosin-Deaminase (SuperCD; ein Fusionsgen der Hefe-
Cytosin-Deaminase und der Hefe-Uracil-Phosphoribosyltransferase) kodieren.
Das SuperCD Suizid-Protein wandelt die klinisch zugelassene, ungiftige Medika-
mentenvorstufe 5-Fluorcytosin in 5-Fluoruracil um, das bei einer Vielzahl von Tu-
moren erfolgreich als Chemotherapeutikum verwendet wird. Die Wirksamkeit die-
ses Masern-Impfvirus-Vektors wurde in drei humanen Cholangiokarzinomzellli-
nen (RBE, TFK-1 und HuCCT1) untersucht.
Alle Zelllinien konnten erfolgreich mit den Masern-Impfviren infiziert werden. In
einer Zelllinie war die Infektions- und Absterberate, welche durch das Virus ver-
ursacht wurden, im Vergleich zu den beiden anderen Zelllinien deutlich reduziert.
Diese Resistenz gegenüber der alleinigen Masern-Impfvirus-Onkolyse konnte
durch die Zugabe von 5-Fluorcytosin durchbrochen werden.
xii
xiii
In mehreren Tierexperimenten wurde die Wirkung dieses armierten Masern-
Impfvirus weiter untersucht: In einem xenogenen subkutanen TFK-1-Mausmodell
führte die intratumorale Gabe des Virus zusammen mit einer systemischen Appli-
kation von 5-FC zu einer signifikanten Verringerung der Tumorgröße im Vergleich
zu der alleinigen Gabe des Virus. In einem zweiten Experiment mit der Zelllinie
HuCCT1 konnte über eine Verringerung der Tumorgröße hinaus auch eine Verlän-
gerung der mittleren Überlebenszeit im Vergleich zu den Kontrolltieren nachgewie-
sen werden.
Diese Ergebnisse haben den Weg zu einer präklinischen Phase-I-Studie geebnet:
Hier wird dieser neuartige Masern-Impfvirus-Vektor (MeV ld-SCD) in Kombina-
tion mit einer oralen Gabe von 5-FC bei Patienten mit fortgeschrittenen, nicht-
resektablen Cholangiokarzinomen eingesetzt.
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